Literature DB >> 15870919

Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues.

Sachiko Ogasawara1, Hirohisa Yano, Seiya Momosaki, Naoyo Nishida, Yumi Takemoto, Sakiko Kojiro, Masamichi Kojiro.   

Abstract

Matrix metalloproteinases (MMPs) relate to the growth and infiltration of cancer cells, but the frequency and amount of their expression are not yet fully examined in hepatocellular carcinoma. Expression of MMPs (MMP-2, MMP-7, MMP-9, MT1-MMP, MT2-MMP, MT3-MMP) and tissue inhibitors of metalloproteinase (TIMP: TIMP-1, TIMP-2) was investigated on cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. The cultured cells and tissues expressed MMPs and TIMPs at various degrees, and high expression was observed for MMP-2, MMP-9, MT1-MMP and TIMP-2. Expression of MMP-7, MT2-MMP and TIMP-1 was found at a low frequency and a low amount in both the cells and the tissues. MMP-2 was expressed in various cells: HCC cells, vascular wall and sinusoidal endothelial cells in the cancer area of surgically resected tissues; and hepatocytes, bile duct cells, vascular wall, macrophages and Kupffer cells in the non-cancerous area. MMPs and TIMPs were expressed at a relatively high frequency in hepatocytes of the cancerous area and surrounding non-cancerous area as well as in the other cells and tissues. MMPs and TIMPs may be involved in the progression of hepatocellular carcinoma including the infiltration of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870919

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.

Authors:  Linping Xu; Hui Yang; Meimei Yan; Wei Li
Journal:  Clin Exp Med       Date:  2022-09-28       Impact factor: 5.057

2.  Epigallocatechingallate inhibits migration of human uveal melanoma cells via downregulation of matrix metalloproteinase-2 activity and ERK1/2 pathway.

Authors:  Chi-Wu Chang; Yi-Hsien Hsieh; Wei-En Yang; Shun-Fa Yang; Yueqin Chen; Dan-Ning Hu
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

3.  Matrix Metalloproteinase 2 Knockdown Suppresses the Proliferation of HepG2 and Huh7 Cells and Enhances the Cisplatin Effect.

Authors:  Jiangwei Liu; Xiaocheng Li; Jianzhao Huang; Yan Liu
Journal:  Open Med (Wars)       Date:  2019-05-17

4.  MiR-4521 plays a tumor repressive role in growth and metastasis of hepatocarcinoma cells by suppressing phosphorylation of FAK/AKT pathway via targeting FAM129A.

Authors:  Munawar Ayesha; Abbasi Majid; Dongting Zhao; Frederick T Greenaway; Naimeng Yan; Qinlong Liu; Shuqing Liu; Ming-Zhong Sun
Journal:  J Adv Res       Date:  2021-05-12       Impact factor: 10.479

Review 5.  Angiogenesis-related non-coding RNAs and gastrointestinal cancer.

Authors:  Zahra Sadat Razavi; Kasra Asgarpour; Maryam Mahjoubin-Tehran; Susan Rasouli; Haroon Khan; Mohammad Karim Shahrzad; Michael R Hamblin; Hamed Mirzaei
Journal:  Mol Ther Oncolytics       Date:  2021-05-15       Impact factor: 7.200

6.  Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods.

Authors:  Lingyan Zhang; Ying Guo; Bibo Li; Juan Qu; Chunbao Zang; Fang Li; Ying Wang; Hua Pang; Shaolin Li; Qingjun Liu
Journal:  Eur J Med Res       Date:  2013-10-01       Impact factor: 2.175

7.  Nonlethal Levels of Zeaxanthin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-κB Pathway in Cultured Human Uveal Melanoma Cells.

Authors:  Ming-Chao Bi; Nicole Hose; Cai-Lian Xu; Chen Zhang; Jodi Sassoon; E Song
Journal:  J Ophthalmol       Date:  2016-01-28       Impact factor: 1.909

Review 8.  Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Florin Graur; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.